Hervé Hoppenot

He has built Incyte into one of the most successful mid-cap biopharmaceutical companies, anchored by Jakafi (ruxolitinib) — the first FDA-approved JAK1/JAK2 inhibitor. Jakafi generates over $2.5 billion in annual revenue treating myelofibrosis, polycythemia vera, and graft-versus-host disease, giving Incyte a stable cash flow foundation. Under Hoppenot, Incyte has diversified its portfolio beyond Jakafi with Opzelura (topical ruxolitinib for atopic dermatitis and vitiligo), Monjuvi (for diffuse large B-cell lymphoma), and a deep pipeline of clinical-stage assets in oncology and inflammation. The company's research focuses on novel mechanisms including PD-L1, FGFR, BET, and bispecific antibodies. Hoppenot has maintained Incyte's strategy of selective partnerships — licensing certain assets to larger pharma companies while retaining US commercial rights. His management of Jakafi lifecycle extension (combating eventual generic competition), execution on the Opzelura dermatology launch, and pipeline clinical trial outcomes are the critical drivers of Incyte's stock price. The concentration risk around Jakafi and the binary nature of clinical trial readouts make his R&D prioritization decisions particularly consequential for shareholders.